Online CME

Series Activities

Series Activities

Cleveland Clinic Tumor Boards

Hormone Receptor-Positive Advanced
Breast Cancer:
Challenges and New Treatment Options

Print this Content

Release Date:  August 23, 2017
Expiration Date:   August 23, 2018

Estimated Time of Completion: 1 hour, 15 minutes

Description

This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaciclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B-42, breast cancer index and other biomarkers.

Learning Objectives

  1. Identify the current standard of care for endocrine therapy in patients with hormone receptor-positive advanced breast cancer
  2. Discuss key results of clinical trials of fulvestrant, alone and in combination regimens, for treatment of HR-positive disease
  3. State the mechanism of action of CDK4/6 inhibitors and rationale for their use in HR-positive advanced breast cancer
  4. Assess the efficacy and safety of CDK4/6 inhibitors observed in recent clinical trials in women with HR-positive, HER2-negative breast cancer and its potential to overcome endocrine resistance
  5. Explain the rationale for use of mTOR inhibitors for treatment of patients with HR-positive advanced breast cancer, and summarize recent clinical trial data supporting the efficacy of such agents in this patient population
  6. Review biomarker driven decision making in adjuvant and extended adjuvant setting

Target Audience

This activity is designed for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Directors
Jame Abraham, MD

Jame Abraham, MD
Director, Breast Oncology Program
Co-director, Comprehensive Breast Cancer Program
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Faculty

G. Thomas Budd, MD
Department of Hematology/Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Maura N. Dickler, MD
Interim Chief, Breast Medicine Service
Section Head, Endocrine Therapy Clinical Research Program
Department of Medicine, Memorial Sloan Kettering Cancer Center
New York City, NY

Richard S. Finn, MD
Associate Professor of Medicine
Department of Medicine
David Geffen School of Medicine at the University of California – Los Angeles
Los Angeles, CA

Gabriel N. Hortobagyi, MD
Program Director
Department of Breast Medical Oncology
Division of Susan G. Komen Interdisciplinary Breast Fellowship Program
Nellie B. Connally Chair in Breast Cancer
Professor of Medicine
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation, could be perceived as a potential conflict of interest:

Jame Abraham, MD
  Genentech/Roche Teaching and Speaking
  Pfizer, Inc. Consulting; Teaching and Speaking
 
Maura N. Dickler, MD
  AstraZeneca Pharmaceuticals; GI Therapeutics, Inc.;
Genetech/Roche; Novartis Pharmaceuticals; Pfizer, Inc.; Syndax
Consulting
  TapImmune Inc. Membership on advisory committee or review panels; DSMB
 
Richard S. Finn, MD
  Bayer Healthcare; Bristol-Myers Squibb Co.; Novartis Oncology;
Pfizer, Inc.
Consulting
 
Gabriel N. Hortobagyi, MD
  Eli Lilly; Novartis Pharmaceuticals; Pfizer, Inc. Membership on advisory committee or review panels

The following faculty has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

G. Thomas Budd, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

AstraZeneca Pharmaceuticals LP
Biotheranostics, Inc.
Lilly USA, LLC
Novartis Pharmaceuticals Corporation

This CME activity was produced by Cleveland Clinic Foundation
Center for Continuing Education, Taussig Cancer Institute and Harborside Press.